Abstract
Intra-arterial chemotherapy for colorectal liver metastases (CLM) has been extensively studied over the last 30 years. In both patients with resectable and unresectable liver metastases, hepatic arterial infusion (HAI) chemotherapy with floxuridine has been shown to be an effective and safe method of treating patients with CLM. As an adjuvant therapy, HAI is associated with markedly improved hepatic progression-free survival and improved overall survival. In the unresectable setting, HAI is associated with high response rates and rates of conversion to complete resection. With careful observation and management to minimize the toxicity of this treatment, HAI chemotherapy via the hepatic artery should be considered as an adjuvant therapy in patients undergoing definitive surgical resection of CLM, as well as those being treated with modern systemic chemotherapy for unresectable disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
